T1	p 84 119	advanced nasopharyngeal carcinoma :
T2	p 202 217	carcinoma ( NPC
T3	p 244 266	chemosensitive tumor .
T4	p 382 410	patients with advanced NPC .
T5	p 432 537	From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to
T6	p 543 556	M0 ) NPC were
T7	p 1642 1657	refused by nine
T8	p 1727 1728	.
T9	p 1845 1890	patients with advanced NPC in endemic areas .
T10	i 25 79	concurrent chemoradiotherapy versus radiotherapy alone
T11	i 319 378	chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone
T12	i 628 630	RT
T13	i 710 756	concurrent chemotherapy with cisplatin 20 mg/m
T14	i 763 792	/d plus fluorouracil 400 mg/m
T15	i 824 832	infusion
T16	i 1286 1293	RT-only
T17	i 1376 1380	CCRT
T18	i 1416 1423	RT-only
T19	i 1614 1641	concurrent chemotherapy was
T20	i 1812 1816	CCRT
T21	i 1832 1840	RT alone
T22	o 139 176	overall and progression-free survival
T23	o 866 883	Survival analysis
T24	o 1141 1154	tumor relapse
T25	o 1208 1237	5-year overall survival rates
T26	o 1317 1355	5-year progression-free survival rates
T27	o 1473 1481	toxicity
T28	o 1520 1554	leukopenia and emesis , compliance
T29	o 1761 1767	deaths